Biotechnology Holding Company

Building What Biotech Becomes Next.

Biocurion is building a portfolio of independent, wholly-owned life science companies — each focused on a large underserved therapeutic need and supported by one integrated holding platform.

Our ModelOur Companies
5Independent Subsidiaries
2026Platform Launch
12–24Month Data Window
SharedInfrastructure
Company Overview

The Biocurion Platform

A holding company model for modern biotech: independent science companies, shared infrastructure, disciplined capital allocation, and multiple development pathways.

Biocurion five-company platform visual
Independent Subsidiaries

Each vertical operates with its own science, IP, leadership, and capital structure — enabling independent scientific development and asset-level focus.

Platform Infrastructure

Shared regulatory expertise, CMC capabilities, clinical strategy, and BD relationships compress timelines and reduce duplicative cost.

Multi-Pathway Architecture

Five verticals, five development pathways: licensing, regulatory strategy, government preparedness, and commercial partnerships.

Programs at Inflection

Programs positioned around IND-enabling work and Phase I/II initiation, with key data readouts in the 12–24 month window.

Our Companies · Platform Architecture

One Holding Platform, Five Independent Subsidiaries.

Each wholly-owned subsidiary is purpose-built around a distinct scientific domain, development pathway, and development pathway.

Oncorion

Precision Oncology

Integrated approaches to cancer diagnosis and treatment through molecular imaging, targeted therapeutics, and data-driven treatment strategies.
Imurion

Rare Pediatric Disease

Targeted imaging and radiopharmaceutical programs designed to accelerate diagnosis and improve care for children with rare diseases.
Alzurion

Neurodegenerative
Diseases

Precision neuroscience platform focused on upstream neuroinflammation, synaptic resilience, and biomarker-guided development.
Insepcion

Infectious Disease

Integrated detection, diagnosis, and targeted therapeutics for sepsis, melioidosis, Ebola, Lassa Fever, and antimicrobial-resistant pathogens.
Radurion

Radiation
Countermeasure
Platform

Radioprotective and radiomitigative therapeutics for acute radiation syndrome, space medicine, oncology care, and military readiness.
How We Create Value

Portfolio-Level Exposure to Biotech Innovation

Biocurion provides exposure to multiple independent biotech companies, multiple scientific domains, multiple clinical pathways, and multiple development pathways.

01 · Identify High-Impact Domains

We select domains where unmet need, regulatory incentives, and validated collaboration markets converge.

02 · Form Independent Companies

Each subsidiary has its own scientific direction, regulatory strategy, IP ownership, and capital structure.

03 · Support Governance & Scale

Biocurion provides strategic oversight, capital allocation, operating support, and structural governance.

04 · Advance Through Partnerships

Each company is structured for its own path: clinical development, regulatory strategy, licensing, government preparedness, or commercial partnership.

Partnering Organizations

Pharmaceutical CompaniesLicensing, co-development, strategic collaboration
Academic InstitutionsResearch collaborations and translational science
Healthcare SystemsClinical validation and trial-site execution
Government AgenciesBARDA, DoD, biodefense, and procurement pathways
Strategic CapitalFamily offices, institutions, and healthcare investors
Manufacturing PartnersCMC, isotope supply, and scale-up infrastructure
Discuss a Partnership →
Leadership Team

Experienced Builders

Across biotech operations, capital markets, clinical development, regulatory affairs, strategic development, and portfolio governance.

Rose Satz

Rose Satz

Chief Executive Officer

Multi-vertical life sciences · Strategic Partnerships

Thom Tulip, PhD

Thom Tulip, PhD

Chief Business Officer

Licensing · Co-development · Pharma partnerships

Colm King

Colm King

Chief Financial Officer

Capital structure · Public company readiness

Alex Tang

Alex Tang

Chief Operating Officer

Portfolio execution · Governance · Operational scaling

Eric Liu, MD

Eric Liu, MD

Chief Medical Officer

Oncology · Rare disease · Nuclear medicine · IND/FDA

Stanley Satz, PhD

Stanley Satz, PhD

Chief Scientific Officer

Preclinical leadership · Molecular medicine · Dx

Sylvia Mergui, PhD

Sylvia Mergui, PhD

VP, Clinical Research & Development

Clinical program management · Site oversight

Brian Burnett, MS

Brian Burnett, MS

Director, Regulatory Affairs

FDA IND/NDA · Orphan Drug · PRV · Gov. submissions

Greg Waterbury

Greg Waterbury

VP, Strategic Development

CMO partnerships · Manufacturing · Supply chain

News Media

Biocurion Updates

Biocurion news, portfolio milestones, strategic transactions, and market developments shaping the future of precision medicine.

Curium to Acquire Lantheus in Transaction Valued at Up to $8 Billion

The combination underscores the strategic value of scaled radiopharmaceutical platforms spanning molecular imaging, targeted therapeutics, manufacturing, and commercial infrastructure.

Read Reuters coverage

Five Focused Companies. One Shared Operating Platform.

Biocurion combines independently valuable scientific companies with disciplined capital allocation, centralized infrastructure, and portfolio-level strategic flexibility.

Explore the platform

Built for Collaboration Across the Development Lifecycle

Biocurion welcomes discussions with pharmaceutical partners, academic institutions, health systems, government agencies, and strategic capital providers.

Connect with Biocurion
Connect With Us

Connect with Biocurion

We welcome inquiries from pharmaceutical partners, clinicians, researchers, academic collaborators, institutional investors, and prospective team members.

General Inquiries

info@biocurion.com

General questions regarding Biocurion and our portfolio companies.

Business Development & Licensing

partnerships@biocurion.com

Licensing, co-development, strategic partnerships, and collaborations.

Clinical & Research

clinical@biocurion.com

Clinical investigators, physician collaborations, and trial opportunities.

Investor Relations

investors@biocurion.com

Institutional investors, family offices, and strategic capital partners.

Media & Press

media@biocurion.com

Press interviews, speaking engagements, and corporate announcements.

Careers

careers@biocurion.com

Scientific, operational, and corporate opportunities.

Headquarters

Biocurion
United States
www.biocurion.com